



POSTER PRESENTATION

Open Access

# Efficacy and safety of combined medium-dose mometasone furoate/formoterol (MF/F) in persistent asthmatics

Robert A Nathan<sup>1\*</sup>, David S Pearlman<sup>2</sup>, Hendrik Nolte<sup>3</sup>, Anjuli Nayak<sup>4</sup>

From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2010  
Victoria, Canada. 3-6 November 2010

## Background

The availability of controller therapies at multiple strengths is important to treat different severities of asthma (NHLBI and GINA guidelines). The clinical effect of medium-dose mometasone furoate/formoterol (MF/F) combination administered via single inhaler had never been characterized in asthmatic subjects versus placebo. We investigated the effect of medium-dose MF/F administered via an MDI on asthma deteriorations (ie, severe asthma exacerbations) and pulmonary function in moderately-severe asthmatics inadequately-controlled on medium-dose inhaled corticosteroids (ICS) ± long-acting  $\beta_2$ -agonists (LABA).

## Materials and methods

After 2-3-weeks open-label run-in with MF 200 $\mu$ g BID, subjects ( $\geq 12$  years) were randomized to 26-weeks treatment BID with MF/F 200/10 $\mu$ g, MF 200 $\mu$ g, F 10 $\mu$ g, or placebo. Coprimary endpoints were time-to-first asthma deterioration over the treatment period (MF/F vs F), and the area under the curve (AUC) of the change in serial FEV<sub>1</sub> [0-12 hr] to Week 12 (MF/F vs MF).

## Results

781 subjects (mean: age=42.4 y, asthma duration=16.07 y, FEV<sub>1</sub> % predicted=72.62%, reversibility=18.80%, ACQ score=1.51) were randomized. MF/F increased the time-to-first asthma deterioration and decreased the proportion of subjects who experienced asthma deteriorations (MF/F=30.4%; MF=33.9% [p=0.565]; F=54.0% [p<0.001]; placebo=55.6% [p<0.001]). MF/F treatment improved lung function more than MF within 5 minutes following

administration (p<0.001); mean Week-12 FEV<sub>1</sub>AUC<sub>0-12h</sub> (L x h over baseline): MF/F=3.11, MF=1.30, F=1.93, and placebo=0.57 (effect was maintained throughout the treatment period). Adverse events were rare and similar across treatment groups.

## Conclusions

MF/F 200/10 $\mu$ g was more effective in reducing asthma deteriorations and improving lung function in asthmatics uncontrolled on medium-dose ICS±LABA than placebo, MF or F.

## Author details

<sup>1</sup>Asthma and Allergy Associates, P.C., Colorado Springs, CO, 80907, USA. <sup>2</sup>Colorado Allergy and Asthma Centers, P.C., Denver, CO, 80230, USA. <sup>3</sup>Merck Research Laboratories, Kenilworth, NJ, 07033, USA. <sup>4</sup>Sneeze, Wheeze, and Itch Associates, Normal, IL, 61761, USA.

Published: 4 November 2010

doi:10.1186/1710-1492-6-S2-P16

Cite this article as: Nathan *et al.*: Efficacy and safety of combined medium-dose mometasone furoate/formoterol (MF/F) in persistent asthmatics. *Allergy, Asthma & Clinical Immunology* 2010 **6**(Suppl 2):P16.

\* Correspondence: DrRNathan@aol.com

<sup>1</sup>Asthma and Allergy Associates, P.C., Colorado Springs, CO, 80907, USA  
Full list of author information is available at the end of the article